Cancer diagnostics will always be a continuously imperfect system, because science creates possibilities faster than evidence, regulation, reimbursement and laboratories can absorb them. It is also in permanent transition between central, decentralized and hybrid delivery, and what must stay constant is that clinically justified testing does not leave patients out for preventable reasons. Managing that…